SCHEMBL105289

SCHEMBL105289

CC(C)NCc1ccoc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
PDE10A Q9Y233 1/20 0.38
MCHR1 Q99705 1/20 0.36
HRH1 P35367 1/20 0.36
LTA4H P09960 1/20 0.36
FAAH O00519 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
CNR2 P34972 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
TSHR P16473 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
ALOX5 P09917 1/20 0.34
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13995894 0.81 ALDH1A1 (0.50) HPGDPDE10AMCHR1FAAHMEN1
SCHEMBL13995950 0.81 ALDH1A1 (0.50) HPGDPDE10AMCHR1FAAHMEN1
SCHEMBL20093550 0.81 HPGD (0.37) HPGDPDE10AMCHR1FAAHMEN1
SCHEMBL19145007 0.81 FAAH (0.34) HPGDPDE10AMCHR1FAAHMEN1
SCHEMBL22571297 0.78 SIGMAR1 (0.38) HPGDSIGMAR1ACACB
SCHEMBL178475 0.76
SCHEMBL11075386 0.74 PDE10A (0.36) HPGDPDE10AMCHR1FAAHMEN1
SCHEMBL11123865 0.74 HPGD (0.36) HPGDPDE10AMCHR1FAAHMEN1
SCHEMBL3271284 0.74 SIGMAR1 (0.48) HRH1LTA4HALDH1A1PTGS2SIGMAR1
SCHEMBL11074304 0.73 PDE10A (0.36) HPGDPDE10AMCHR1HRH1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312498-A1 NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS UNIVERSITY OF MARYLAND, BALTIMORE 2023-10-05 US disclosed
US-11718595-B2 Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-08-08 US disclosed
US-20230140941-A1 NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2023-05-11 US disclosed
US-20210317097-A1 NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS UNIVERSITY OF MARYLAND, BALTIMORE 2021-10-14 US disclosed
WO-2021183970-A1 NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-09-16 WO disclosed
WO-2020118194-A1 NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-06-11 WO disclosed
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-07-20 US disclosed
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-07-20 US disclosed
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-02 US disclosed
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION ONCOTHERAPY SCIENCE, INC. (JP) 2012-03-08 US disclosed
US-7423066-B2 Dietetics; use in treatment of obesity, for reducing body weight, modulating body lipid metabolism, and reducing food intake THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-09 US disclosed
US-20080103209-A1 Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-01 US disclosed
US-20070203183-A1 Diaryl piperidines as CB1 modulators SCHERING CORPORATION 2007-08-30 US disclosed
US-20070203183-A1 Diaryl piperidines as CB1 modulators SCHERING CORPORATION 2007-08-30 US disclosed
EP-1324985-A4 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 2004-10-06 EP disclosed
EP-1324985-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2003-07-09 EP disclosed
WO-2002028831-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059162-A1 FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION NR0B1, GRK7, NR5A2 HPGD 4110/4885PDE10A 2627/4885MCHR1 1652/4885
US-20230140941-A1 NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS MAPK1, MAPK8, MAPK4 HPGD 1216/4885PDE10A 1821/4885MCHR1 4442/4885
US-20080103209-A1 Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists FAAH, CNR2, FAAH2 HPGD 187/4885PDE10A 696/4885MCHR1 1871/4885
US-20070203183-A1 Diaryl piperidines as CB1 modulators CNR1, CNR2, GPR119 HPGD 3112/4885PDE10A 895/4885MCHR1 1018/4885
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME HSPH1, HBZ, PITHD1 HPGD 1379/4885PDE10A 2971/4885MCHR1 2344/4885
US-20210317097-A1 NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS MAPK1, MAPK8, MAPK4 HPGD 1192/4885PDE10A 1838/4885MCHR1 4418/4885
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY CFTR, HSP90B1, SERPINB1 HPGD 967/4885PDE10A 420/4885MCHR1 3861/4885
US-20230312498-A1 NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS MAPK1, MAPK8, MAPK4 HPGD 1192/4885PDE10A 1838/4885MCHR1 4418/4885
US-11718595-B2 Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors MAPK1, MAPK8, MAPK4 HPGD 1192/4885PDE10A 1838/4885MCHR1 4418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.